VA
ALNY icon

Vident Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vident Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14M Buy
6,457
+1,302
+25% +$443K 0.02% 605
2025
Q4 		$2.05M Sell
5,155
-82
-2% -$36.3K 0.02% 576
2025
Q3 		$2.39M Buy
5,237
+1,312
+33% +$534K 0.02% 510
2025
Q2 		$1.28M Buy
3,925
+1,258
+47% +$348K 0.01% 644
2025
Q1 		$720K Buy
2,667
+1,340
+101% +$344K 0.01% 849
2024
Q4 		$312K Buy
1,327
+232
+21% +$61K 0.01% 1156
2024
Q3 		$301K Sell
1,095
-654
-37% -$170K 0.01% 1132
2024
Q2 		$425K Buy
1,749
+188
+12% +$29.7K 0.01% 980
2024
Q1 		$233K Sell
1,561
-308
-16% -$51.4K ﹤0.01% 1147
2023
Q4 		$358K Buy
1,869
+124
+7% +$21.1K 0.01% 917
2023
Q3 		$309K Buy
+1,745
New +$333K 0.01% 884

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Advisory's ALNY Position: Q1 2026 in Review

Vident Advisory increased its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q1 2026, buying an estimated $443K and bringing the position to 6,457 shares worth $2.14M. The position accounts for 0.02% of the portfolio, ranked #605.

Vident Advisory first reported a position in ALNY in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.39M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Vident Advisory held 6,457 shares of Alnylam Pharmaceuticals worth $2.14M as of Q1 2026.
  • Vident Advisory bought 1,302 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $443K.
  • Alnylam Pharmaceuticals made up 0.02% of Vident Advisory's portfolio in Q1 2026, its #605 holding.
  • Vident Advisory first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Vident Advisory's Alnylam Pharmaceuticals position peaked at $2.39M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.